Bio-Techne Corporation · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-01-21$71.38 RISE2026-05-15$43.30 PEAK2026-05-29$51.68 128d | -39.3% 114d | Missed | Missed | — | — | +19.4% 14d | Missed |
DROP2026-01-21$71.38 RISE2026-03-16$48.81 PEAK2026-04-20$60.58 89d | -31.6% 54d | Missed | Missed | — | — | +24.1% 35d | Missed |
DROP2025-03-27$59.95 RISE2025-08-06$49.87 PEAK2025-10-23$66.06 210d | -16.8% 132d | Missed | Missed | — | — | +32.5% 78d | Missed |
DROP2025-01-21$78.75 RISE2025-05-21$46.66 PEAK2025-07-25$58.78 185d | -40.7% 120d | Missed | Missed | — | — | +26.0% 65d | Missed |
DROP2024-08-01$82.35 RISE2024-11-19$66.37 PEAK2025-01-21$78.75 173d | -19.4% 110d | Missed | Missed | — | — | +18.7% 63d | Missed |
DROP2024-05-14$84.15 RISE2024-07-02$71.24 PEAK2024-08-01$82.35 79d | -15.3% 49d | Missed | Missed | — | — | +15.6% 30d | Missed |
DROP2023-12-28$78.22 RISE2024-04-19$62.12 PEAK2024-05-14$84.15 138d | -20.6% 113d | Missed | Missed | — | — | +35.5% 25d | Missed |
DROP2023-12-28$78.22 RISE2024-02-02$65.98 PEAK2024-03-08$77.09 71d | -15.6% 36d | Missed | Missed | — | — | +16.8% 35d | Missed |
DROP2023-07-21$89.42 RISE2023-11-01$52.83 PEAK2023-12-28$78.22 160d | -40.9% 103d | Missed | Missed | — | — | +48.1% 57d | Missed |
DROP2022-11-15$88.07 RISE2023-03-28$71.62 PEAK2023-05-03$85.98 169d | -18.7% 133d | Missed | Missed | — | — | +20.1% 36d | Missed |
DROP2022-08-03$97.96 RISE2022-10-11$70.50 PEAK2022-11-15$88.07 104d | -28.0% 69d | 2022-08-26 $84.68 | 2022-11-15 $88.07 | 62Quality on Sale | 54Watch | +24.9% 35d | +4.0% Held 81d |
DROP2022-04-07$112.41 RISE2022-06-16$80.67 PEAK2022-08-03$97.96 118d | -28.2% 70d | Missed | Missed | — | — | +21.4% 48d | Missed |
DROP2021-12-31$129.34 RISE2022-05-11$84.67 PEAK2022-08-03$97.96 215d | -34.5% 131d | Missed | Missed | — | — | +15.7% 84d | Missed |
DROP2021-09-24$134.72 RISE2022-01-27$88.46 PEAK2022-04-07$112.41 195d | -34.3% 125d | Missed | Missed | — | — | +27.1% 70d | Missed |
DROP2021-02-16$102.75 RISE2021-03-08$86.22 PEAK2021-04-27$110.35 70d | -16.1% 20d | Missed | Missed | — | — | +28.0% 50d | Missed |
1–15 / 17 1 / 2 | |||||||
While Bio-Techne has lagged behind the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.
While Bio-Techne has lagged behind the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand. The result? Over the past six months, the industry’s 1.8% return has trailed the S&P 500 by 9 percentage points.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand. The result? Over the past six months, the industry’s 1.8% return has trailed the S&P 500 by 9 percentage points.
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Tuesday. Discover which stocks are leading as top gainers and losers in today's session.
Stay informed about the performance of the S&P500 index in the middle of the day on Tuesday. Uncover the top gainers and losers in today's session for valuable insights.
The Caviar Cruise stock screening strategy identifies quality companies with sustainable advantages. Bio-Techne Corp (TECH) passes with 25.48% ROIC, strong cash flow, and minimal debt, making it a compelling long-term investment candidate.
Bio-Techne’s first quarter was marked by a negative market reaction, with revenue coming in below Wall Street expectations. Management attributed the shortfall primarily to continued softness in emerging biotech demand and the impact of order timing from two cell therapy customers with FDA Fast Track Designation. CEO Kim Kelderman acknowledged that, despite stable performance from large pharmaceutical customers and improving trends in U.S. academia, the emerging biotech segment “was indeed our s
Bio-Techne’s first quarter was marked by a negative market reaction, with revenue coming in below Wall Street expectations. Management attributed the shortfall primarily to continued softness in emerging biotech demand and the impact of order timing from two cell therapy customers with FDA Fast Track Designation. CEO Kim Kelderman acknowledged that, despite stable performance from large pharmaceutical customers and improving trends in U.S. academia, the emerging biotech segment “was indeed our s
RBC Capital analyst Dan Leonard reinstates Bio-Techne (NASDAQ:TECH) with a Outperform and announces $62 price target.
Baron Capital, an investment management company, released its Q1 2026 investor letter for the “Baron Asset Fund”. A copy of the letter is available to download here. U.S. equity markets started the year on a positive note. In February, market dynamics changed due to concerns about AI disruption, accelerated by U.S. and Israeli military action in […]
Baron Capital, an investment management company, released its Q1 2026 investor letter for the “Baron Asset Fund”. A copy of the letter is available to download here. U.S. equity markets started the year on a positive note. In February, market dynamics changed due to concerns about AI disruption, accelerated by U.S. and Israeli military action in […]
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
Curious about the top performers within the S&P500 index one hour before the close of the markets on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Get insights into the S&P500 index performance on Wednesday. Explore the top gainers and losers within the S&P500 index in today's session.
Bio-Techne Corporation's ( NASDAQ:TECH ) earnings announcement last week didn't impress shareholders. However, our...
Bio-Techne Corporation's ( NASDAQ:TECH ) earnings announcement last week didn't impress shareholders. However, our...
Bio-Techne Corporation (TECH) Bank of America Global Healthcare Conference 2026 May 12, 2026 12:20 PM EDTCompany ParticipantsKim Kelderman - CEO, President...
Presenter SpeechMichael Ryskin My name is Mike Ryskin. I'm one the Bank of America Life Science Tools and Diagnostics team. And we're excited to be joined by Bio-Techne. We're pleased to host Kim...
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| TECH | -6.07% | -10.62% | -12.12% | +6.78% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -9.04% | -4.90% | -8.68% | -5.91% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| FidelityFMR | fundamental | 7.90M | $412.85M | 0.02% | Added+678.3% | 2026-03-31 |
| StateStreet | passive | 5.87M | $306.68M | 0.01% | Added+1.0% | 2026-03-31 |
| Wellington | fundamental | 5.12M | $267.58M | 0.05% | Trimmed-10.7% | 2026-03-31 |
| CapResearch | fundamental | 3.19M | $166.62M | 0.03% | Added+96.9% | 2026-03-31 |
| Citadel | multi-strat | 295.0K | $15.41M | 0.02% | New | 2026-03-31 |
| TwoSigma | quant | 66.1K | $3.45M | 0.00% | Added+9.6% | 2026-03-31 |
| Bridgewater | macro | 6.0K | $312.36K | 0.00% | New | 2026-03-31 |
| TRowePrice | fundamental | 2.45M | $127.90K | 0.01% | Trimmed-39.9% | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-12 | Herr Amy E. | Director | M Option exercise(deriv) | 6,636 | — | +$0 |
| 2026-05-12 | Herr Amy E. | Director | S Open-market sale | 6,636 | $48.28 | −$320.4K |
| 2026-05-12 | Herr Amy E. | Director | M Option exercise | 6,636 | $47.60 | +$315.9K |
| 2026-05-07 | Kelderman Kim | Chief Executive Officer | M Option exercise(deriv) | 26,692 | — | +$0 |
| 2026-05-07 | Kelderman Kim | Chief Executive Officer | F Tax withholding | 23,951 | $56.68 | −$1.36M |
| 2026-05-07 | Kelderman Kim | Chief Executive Officer | M Option exercise | 26,692 | $47.60 | +$1.27M |
| 2026-05-07 | Bohnen Shane | SVP - General Counsel | M Option exercise(deriv) | 8,400 | — | +$0 |
| 2026-05-07 | Bohnen Shane | SVP - General Counsel | F Tax withholding | 7,055 | $56.68 | −$399.9K |
| 2026-05-07 | Bohnen Shane | SVP - General Counsel | M Option exercise | 8,400 | $47.60 | +$399.8K |
| 2026-05-07 | Hippel James | CFO | M Option exercise(deriv) | 62,000 | — | +$0 |
| 2026-05-07 | Hippel James | CFO | F Tax withholding | 56,955 | $56.68 | −$3.23M |
| 2026-05-07 | Hippel James | CFO | M Option exercise | 62,000 | $47.60 | +$2.95M |
| 2026-05-05 | Crouse Steven C. | President - Diag & Spatial Bi | M Option exercise(deriv) | 794 | — | +$0 |
| 2026-05-05 | Crouse Steven C. | President - Diag & Spatial Bi | F Tax withholding | 311 | $55.02 | −$17.1K |
| 2026-05-05 | Crouse Steven C. | President - Diag & Spatial Bi | M Option exercise | 794 | — | — |
| 2026-04-24 | Hippel James | CFO | M Option exercise(deriv) | 62,000 | — | +$0 |
| 2026-04-24 | Hippel James | CFO | F Tax withholding | 56,097 | $58.58 | −$3.29M |
| 2026-04-24 | Hippel James | CFO | M Option exercise | 62,000 | — | +$0 |
| 2026-04-24 | Kelderman Kim | Chief Executive Officer | M Option exercise(deriv) | 11,344 | — | +$0 |
| 2026-04-24 | Kelderman Kim | Chief Executive Officer | F Tax withholding | 1,363 | $58.58 | −$79.8K |
| 2026-04-24 | Kelderman Kim | Chief Executive Officer | M Option exercise | 11,344 | — | +$0 |
| 2026-04-16 | Kelderman Kim | Chief Executive Officer | M Option exercise(deriv) | 36,500 | — | +$0 |
| 2026-04-16 | Kelderman Kim | Chief Executive Officer | F Tax withholding | 32,088 | $58.66 | −$1.88M |
| 2026-04-16 | Kelderman Kim | Chief Executive Officer | M Option exercise | 36,500 | — | +$0 |
| 2026-04-07 | Bohnen Shane | SVP - General Counsel | M Option exercise(deriv) | 2,259 | — | +$0 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-05upcoming | 0.52 | — | — |
| 2026-05-06 | 0.53 | 0.53 | -0.82% |
| 2026-02-04 | 0.43 | 0.46 | +5.84% |
| 2025-11-05 | 0.25 | 0.24 | -4.00% |
| 2025-08-06 | 0.50 | 0.53 | +5.79% |
| 2025-05-07 | 0.51 | 0.56 | +10.41% |
| 2025-02-05 | 0.39 | 0.42 | +7.77% |
| 2024-10-30 | 0.38 | 0.42 | +10.24% |
| 2024-08-07 | 0.49 | 0.49 | -0.96% |
| 2024-05-01 | 0.46 | 0.48 | +5.27% |
| 2024-02-01 | 0.41 | 0.40 | -3.12% |
| 2023-10-31 | 0.44 | 0.41 | -5.77% |
| 2023-08-08 | 0.55 | 0.55 | +0.34% |
| 2023-05-03 | 0.53 | 0.53 | -0.20% |
| 2023-02-02 | 0.49 | 0.47 | -3.72% |
| 2022-11-01 | 0.46 | 0.45 | -2.74% |